Study of graft-versus-host disease after bone marrow transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows people after an allogeneic bone marrow transplant to understand a complication called graft-versus-host disease. If you can attend follow-up visits, your experience and samples may be compared with a family control to look for differences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- You received an allogeneic (donor) bone marrow transplant at QMH during the past two years
- You did not have an autologous (your own) transplant
- You can attend required follow-up visits
- Be willing to provide samples during follow-up (like tear and stool/microbiome samples if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who are at least 3 years out from their first stem cell transplant to learn how they are doing long term. It may help improve future transplant care by tracking outcomes over time.
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This study looks at immune cells in the blood and tissues of people who have had a stem cell transplant. It aims to understand chronic graft-versus-host disease (GVHD), a common complication, so doctors can better detect and treat it.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.